Advanced search
Publication Cover
Current Medical Research and Opinion Volume 26, 2010 - Issue 3
Submit an article Journal homepage
245
Views
8
CrossRef citations to date
0
Altmetric
Brief Report

Risk reduction of non-vertebral fractures with intravenous ibandronate: post-hoc analysis from DIVA

Philip Sambrook Kolling Institute, Royal North Shore Hospital, St Leonards, Sydney, AustraliaCorrespondence[email protected]
,
Ann Cranney Ottawa Health Research Institute, Ottawa, Canada
&
Jonathan D. Adachi Michael DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada
Pages 599-604 | Accepted 25 Nov 2009, Published online: 08 Jan 2010

Citations (8)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Violet S. Lagari, Elizabeth McAninch & Sanford Baim. (2015) Considerations regarding adherence of anti-osteoporosis therapy. Postgraduate Medicine 127:1, pages 92-98.
Read now

Articles from other publishers (7)

Diogo Mendes, Ana Penedones, Carlos Alves, Tânia Oliveira, António Donato & Francisco Batel-Marques. (2023) Ibandronate in the Prevention of Vertebral and Nonvertebral Osteoporotic Fractures. JCR: Journal of Clinical Rheumatology 29:2, pages 78-83.
Crossref
Gillian M. Keating. (2016) Ibandronate: A Review in Japanese Patients with Osteoporosis. Drugs & Aging 33:4, pages 295-303.
Crossref
Samara Ferguson, Maurille Feudjo Tepie, Andrew Taylor, Andrew Roddam, Cathy Critchlow, Mazhar Iqbal, Leslie Spangler & Jonathan Bayly. (2015) The impact of persistence with bisphosphonates on health resource utilization and fracture risk in the UK : a study of patient records from the UK C linical P ractice R esearch D atalink . Journal of Evaluation in Clinical Practice 22:1, pages 31-39.
Crossref
Kiyohiko Nakai, Satofumi Iida, Masato Tobinai, Junko Hashimoto & Takehiko Kawanishi. (2014) Application of Modeling and Simulation to a Long-Term Clinical Trial: A Direct Comparison of Simulated Data and Data Actually Observed in Japanese Osteoporosis Patients Following 3-Year Ibandronate Treatment. Clinical Pharmacokinetics 54:3, pages 295-304.
Crossref
Toshitaka Nakamura, Tetsuo Nakano, Masako Ito, Hiroshi Hagino, Junko Hashimoto, Masato Tobinai & Hideki Mizunuma. (2013) Clinical Efficacy on Fracture Risk and Safety of 0.5 mg or 1 mg/month Intravenous Ibandronate Versus 2.5 mg/day Oral Risedronate in Patients with Primary Osteoporosis. Calcified Tissue International 93:2, pages 137-146.
Crossref
Terry J. Aspray & Roger M. Francis. (2012) Treatment of osteoporosis in women intolerant of oral bisphosphonates. Maturitas 71:1, pages 76-78.
Crossref
Henrique Pierotti Arantes, André Gonçalves da Silva & Marise Lazaretti-Castro. (2010) Bisphosphonates in the treatment of metabolic bone diseases. Arquivos Brasileiros de Endocrinologia & Metabologia 54:2, pages 206-212.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.